Quince Therapeutics, Inc. (QNCX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Quince Therapeutics, Inc. (QNCX) has a cash flow conversion efficiency ratio of -0.174x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.89 Million) by net assets ($108.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Quince Therapeutics, Inc. worth for the company's overall valuation and market capitalisation.
Quince Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Quince Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Quince Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quince Therapeutics, Inc. ranked by their cash flow conversion efficiency. Explore earnings quality score of Quince Therapeutics, Inc. to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kyobo 8 Special Purpose Acquisition Company
KQ:307280
|
0.059x |
|
Chembond Chemicals Ltd
NSE:CHEMBOND
|
-0.023x |
|
Xiabuxiabu Catering Management (China) Holdings Co. Ltd
F:0XI
|
0.589x |
|
Zhejiang Yuancheng Landscape
SHG:603388
|
0.003x |
|
Bayu Buana Tbk
JK:BAYU
|
-0.131x |
|
Sungmoon Elect
KO:014910
|
0.013x |
|
Kein Hing International Bhd
KLSE:7199
|
0.008x |
|
NextCure Inc
NASDAQ:NXTC
|
-0.800x |
Annual Cash Flow Conversion Efficiency for Quince Therapeutics, Inc. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Quince Therapeutics, Inc. from 2017 to 2025. View today's stock price for Quince Therapeutics, Inc. for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-35.71 Million | $-41.42 Million | 1.160x | +209.60% |
| 2024-12-31 | $30.15 Million | $-31.90 Million | -1.058x | -392.27% |
| 2023-12-31 | $85.08 Million | $-18.29 Million | -0.215x | +50.89% |
| 2022-12-31 | $100.59 Million | $-44.04 Million | -0.438x | +17.51% |
| 2021-12-31 | $118.59 Million | $-62.93 Million | -0.531x | -79.89% |
| 2020-12-31 | $172.26 Million | $-50.82 Million | -0.295x | -2.37% |
| 2019-12-31 | $115.48 Million | $-33.28 Million | -0.288x | -75.98% |
| 2018-12-31 | $71.42 Million | $-11.70 Million | -0.164x | -133.79% |
| 2017-12-31 | $-20.28 Million | $-9.83 Million | 0.485x | -- |
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disord… Read more